851319-32-9 Usage
Description
N-(4-METHYL-3-NITROPHENYL)-4-CHLOROMETHYLBENZAMIDE, with the chemical abstracts service number 851319-32-9, is a synthetic compound that plays a significant role in the field of organic synthesis. Its unique molecular structure, featuring a 4-methyl-3-nitrophenyl group attached to a benzamide with a 4-chloromethyl substituent, endows it with versatile reactivity and potential applications in chemical research and development.
Uses
Used in Organic Synthesis:
N-(4-METHYL-3-NITROPHENYL)-4-CHLOROMETHYLBENZAMIDE is used as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its presence of both electron-donating and electron-withdrawing groups, along with the reactivity of the chloromethyl group, makes it a valuable building block for the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N-(4-METHYL-3-NITROPHENYL)-4-CHLOROMETHYLBENZAMIDE is utilized as a precursor in the development of new drugs. Its ability to form diverse chemical entities through reactions such as nucleophilic substitution, addition, and rearrangement reactions allows for the exploration of novel therapeutic agents with potential medicinal properties.
Used in Research and Development:
N-(4-METHYL-3-NITROPHENYL)-4-CHLOROMETHYLBENZAMIDE is also employed in academic and industrial research settings. It serves as a model compound for studying reaction mechanisms, testing new synthetic methodologies, and evaluating the efficiency of catalysts in organic transformations.
Used in Material Science:
In the field of material science, this compound may find applications in the synthesis of functional materials, such as polymers with specific properties or organic compounds with potential use in optoelectronics, sensors, or other high-tech applications.
While the specific uses of N-(4-METHYL-3-NITROPHENYL)-4-CHLOROMETHYLBENZAMIDE may vary depending on the industry and the desired outcome, its role in organic synthesis and its potential applications across various sectors highlight its importance in the realm of chemistry and material science.
Check Digit Verification of cas no
The CAS Registry Mumber 851319-32-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,1,3,1 and 9 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 851319-32:
(8*8)+(7*5)+(6*1)+(5*3)+(4*1)+(3*9)+(2*3)+(1*2)=159
159 % 10 = 9
So 851319-32-9 is a valid CAS Registry Number.
851319-32-9Relevant articles and documents
Synthesis, in vitro and in vivo evaluation of 18F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors
Prause, Martin,Niedermoser, Sabrina,W?ngler, Carmen,Decristoforo, Clemens,Seibold, Uwe,Riester, Stephanie,Taguchi, Takahiro,Schirrmacher, Ralf,Fricker, Gert,W?ngler, Bj?rn
, p. 1 - 11 (2017/11/28)
Introduction Gastrointestinal stromal tumors (GIST) have a wide range of mutations, but can mostly be treated with Imatinib, until eventually resistance towards this tyrosine kinase inhibitor is acquired. Early and non-invasive determination of the sensitivity of the tumor and its metastases towards Imatinib by positron emission tomography (PET) would be beneficial for therapy planning and monitoring. Methods We developed a synthesis strategy towards the precursor molecule, performed the 18F-synthesis and in the following evaluated the radioligand in vitro regarding its lipophilicity, stability and biological activity (KIT binding properties) as well as its in vivo properties in GIST tumor-bearing mice. Results [18F]fluoronorimatinib could be obtained in an overall radiochemical yield of 22.2 ± 3.3% within 90 min. The radioligand showed high GIST cell uptake and was able to distinguish between Imatinib-sensitive and resistant tumor cell lines (GIST-T1, GIST882, GIST430) in vitro. Further biological evaluations of the ligand towards 9 different GIST-relevant KIT mutations showed comparable binding affinities compared to the structural lead Norimatinib (65 nM vs. 53 nM for wt-KIT). The in vivo evaluation of the newly developed radioligand showed tumor-to-background-ratios comparable to previously described, similar radiotracers. Conclusions Thus, [18F]fluoronorimatinib is able to distinguish between Imatinib-resistant and sensitive KIT mutations. Although no improvement of in vivo tumor-to-background ratios could be achieved compared to formerly described radioligands, the hepatic uptake could be considerably reduced, being advantageous for the imaging of GIST. Advances in knowledge and implications for patient care: We were able to show that it is possible to significantly reduce the unfavorably high hepatic uptake of small-molecule radioligands applicable for GIST PET imaging. This work can thus be the basis for further work intending to develop a PET-radioligand for Imatinib-dependent GIST imaging.
